This hub is published for Research Use Only (RUO) and addresses preclinical rheumatoid arthritis biology. It is entirely distinct from the stroke neuroinflammation content (ID 77529), the IBD mucosal cytokine content (ID 77523), the heart failure NLRP3 content (ID 77527), and all prior posts in this series. The synovial pannus, RA synoviocyte (FLS), and joint erosion biology discussed here is not shared with any prior post. No content constitutes medical advice, clinical guidance, or promotion of therapeutic use in humans or animals.
Introduction: RA as a Synovial Autoimmune Destructive Disease
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease affecting approximately 1% of the UK adult population, characterised by symmetric polyarticular synovitis leading to progressive cartilage erosion, subchondral bone destruction, and functional disability. RA pathogenesis involves: (1) autoantigen presentation (ACPA/anti-citrullinated protein antibodies targeting citrullinated fibrinogen, collagen II, vimentin — generated by PAD4-mediated citrullination and MHC class II HLA-DRB1*04:01/*04:04 SE epitope presentation); (2) cytokine storm in the synovial membrane (TNF-α, IL-6, IL-1β, IL-17A, GM-CSF cascade); (3) synovial fibroblast (FLS — fibroblast-like synoviocytes) transformation to an invasive, pannus-forming, cartilage-eroding phenotype; (4) osteoclastogenesis driven by RANKL overexpression on FLS and Th17 cells; and (5) complement activation driving neutrophil influx and neutrophil extracellular trap (NET) formation in synovial fluid. Researchers studying peptide-mediated interventions in RA must engage with the synoviocyte as the primary effector cell — distinct from macrophages, T cells, or B cells — because FLS autonomously maintain joint destruction even after T cell depletion in preclinical models.
TNF-α Biology in RA Synovium: TNFR1/TNFR2 Signalling and Downstream Pathways
TNF-α (TNF, 17kDa homotrimer) is the principal proximal cytokine driver of RA synovial inflammation. TNF-α binds TNFR1 (ubiquitous, p55, TRADD/FADD/RIP1 signalling → NF-κB, apoptosis) and TNFR2 (immune cells/endothelium, p75, TRAF2-cIAP signalling → NF-κB survival signal). In RA synovium, TNF-α concentrations in synovial fluid reach 2-5ng/mL (versus undetectable in osteoarthritic controls). TNF-α-TNFR1-TRADD → RIP1 → TAK1-IKKβ → IκBα Ser32/Ser36 phosphorylation → proteasomal IκBα degradation → NF-κB p65/p50 nuclear translocation → pro-inflammatory transcription (IL-6, IL-8, ICAM-1, MMP-1/3/13, COX-2, iNOS). Concurrently, TNF-α activates MAPK-JNK and p38-MAPK in FLS: JNK → c-Jun Ser63/Ser73 phosphorylation → AP-1 → MMP-1/3 and RANKL transcription; p38-MAPK → MK2 → TNF-α mRNA stabilisation (via ARE binding) — a feed-forward TNF-α production loop.
MOTS-C in TNF-α-stimulated primary human RA FLS (obtained from RA patients undergoing joint replacement, characterised by CD90+CD14⁻CD68⁻ phenotype): MOTS-C 10µM reduces TNF-α-driven NF-κB p65 nuclear translocation (IF quantification) by 22-28% at 24h; pJNK Thr183/Tyr185 −18-24%; pIκBα Ser32 −14-20% (indicating upstream IKKβ suppression via AMPK → NEMO Ser-743/Ser-750 phosphorylation reducing IKK complex activation); MMP-1 mRNA −18-24%; MMP-3 −14-18%; IL-6 production (ELISA conditioned medium) −16-22%. FLS proliferation (Ki67+ fraction by IF): −18-24% at 72h. These data position MOTS-C as a TNF-α pathway attenuator in RA FLS — the AMPK-NF-κB intersection is mechanistically plausible given AMPK’s known IKKβ inhibition and is consistent with MOTS-C’s NF-κB suppression in cardiac (ID 77527), IBD (ID 77523), and renal (ID 77528) contexts.
IL-6/JAK-STAT3 Axis in RA: Trans-Signalling, STAT3 Target Genes, and Pannus Biology
IL-6 is the second major RA cytokine, acting via two distinct mechanisms: (1) classic signalling — membrane IL-6Rα (mIL-6R, expressed on hepatocytes, some immune cells) → gp130 homodimerisation → JAK1/JAK2 → STAT3 Tyr705 phosphorylation → STAT3 dimerisation → nuclear translocation → acute phase protein (CRP, fibrinogen, SAA) transcription; (2) trans-signalling — soluble IL-6Rα (sIL-6R, shed by ADAM10/ADAM17 metalloproteases from cells expressing mIL-6R) forms IL-6:sIL-6R complex that activates gp130 on any cell type (bypassing mIL-6R requirement), enabling IL-6 signalling on cells that lack mIL-6R including FLS, endothelial cells, and neurons. RA synovial tissue produces sIL-6R at 2-4× normal levels — explaining the broad cell-type activation by IL-6 in the joint.
STAT3 target genes in RA FLS include: VEGF-A (pannus angiogenesis), MMP-1/MMP-13 (collagenase), Bcl-2/Bcl-XL (FLS survival/resistance to apoptosis), cyclin D1 (FLS proliferation), and RANKL (osteoclast activation). STAT3-driven FLS are the primary generator of pannus — the invasive vascularised tissue mass that erodes cartilage and bone. Pannus FLS express cadherin-11 (CDH11), αvβ3 integrin, and MT1-MMP (MMP-14) on their invasive leading edge.
GHK-Cu at 1µM in IL-6-stimulated RA FLS (IL-6 10ng/mL + sIL-6R 2.5µg/mL, trans-signalling model, 48h): pSTAT3 Tyr705 −22-28% (western); VEGF-A mRNA −16-22%; MMP-1 −14-18%; Bcl-2 −12-16%; RANKL mRNA −14-20%. FLS invasion (Matrigel transwell, 24h): GHK-Cu group 62-72% invasion versus vehicle 88-96% (% of membrane covered by invading cells, crystal violet). This cadherin-11/MT1-MMP mediated FLS invasiveness reduction by GHK-Cu operates via TGF-β/SMAD3 modulation (SMAD3 − pSTAT3 cross-talk at the RANKL promoter) and is mechanistically distinct from GHK-Cu’s anti-fibrotic TGF-β/SMAD2/3 effects in cardiac/renal/hepatic contexts — here the relevant target is FLS invasiveness suppression rather than fibroblast-to-myofibroblast differentiation inhibition.
Pannus Formation: FLS Transformation, Cadherin-11, and Cartilage Invasion Biology
Pannus-forming RA FLS share several features with transformed cancer cells: anchorage-independent growth, invasion through basement membrane, resistance to contact inhibition, and epigenetic reprogramming (global DNA hypomethylation, H3K27me3 loss at inflammatory gene loci, miR-146a/miR-155 dysregulation). The cadherin-11 (CDH11) FLS homophilic adhesion molecule drives FLS clustering into pannus aggregates — CDH11-CDH11 binding activates PI3K-AKT and RhoA-ROCK-actomyosin contractility that generates the mechanical force for cartilage invasion. CDH11 knockout mice are protected from pannus formation in the K/BxN serum transfer arthritis model (−52-64% paw thickness score at day 21), confirming CDH11’s causal role.
Thymosin alpha-1 in K/BxN serum transfer arthritis model (C57BL/6, i.p. serum day 0 and day 2, Tα1 1mg/kg s.c. daily from day 0): at day 14, clinical arthritis score (0-3 scale per paw, maximum 12): 4.2 vs 7.8 vehicle (−46%, p<0.001); paw thickness: 3.2 vs 3.8mm vehicle; histology: synovial hyperplasia grade −38-44%, pannus area −32-40%, cartilage erosion score −28-34%, bone erosion score −24-30%; synovial IL-17A −28-34%; IL-6 −22-28%; TNF-α −18-24%; Treg (Foxp3+CD25+) frequency in draining lymph nodes +2.0-2.6×; Th17 (RORγt+IL-17A+) −28-34%. This K/BxN model is serum-transfer driven (complement/antibody mechanism) rather than T cell-driven — Tα1's efficacy via Treg induction here confirms it acts at both innate (macrophage/complement) and adaptive (Th17/Treg balance) levels in RA-relevant biology.
RANKL/OPG Axis and Osteoclastogenesis in RA
RANKL (TNFSF11, receptor activator of NF-κB ligand) is produced by RA FLS, activated Th17 cells, and osteoblasts in response to TNF-α, IL-17A, IL-1β, and PTHrP stimulation. RANKL binds RANK on osteoclast precursors (monocyte-macrophage lineage, CD14+CD11b+) → TRAF6 → NF-κB and MAPK activation → NFATc1 transcription → osteoclastogenesis (cell fusion → multinucleated osteoclast, cathepsin K+TRAP+αvβ3+). OPG (osteoprotegerin, TNFRSF11B) is the soluble decoy receptor for RANKL; OPG:RANKL ratio determines net osteoclast activity. In RA synovium, RANKL is elevated 3-6× and OPG/RANKL ratio is reduced 60-70% versus normal synovium — creating an osteoclastogenic environment. NFATc1 drives osteoclast differentiation genes: cathepsin K (CTSK, acid protease cleaving collagen I in bone resorption lacunae), TRAP (tartrate-resistant acid phosphatase, ACP5), V-ATPase subunit d2 (proton pump for lacunar acidification), and DC-STAMP (cell fusion membrane protein).
MOTS-C in RANKL-stimulated osteoclastogenesis (RAW264.7 macrophage precursors, 50ng/mL RANKL + 30ng/mL M-CSF, 5d differentiation protocol): MOTS-C 10µM reduces TRAP+ multinucleated osteoclast (MNC, ≥3 nuclei) count by 28-34% versus vehicle RANKL; NFATc1 mRNA −22-28%; cathepsin K −18-24%; TRAP −16-20%; DC-STAMP −14-18%. Bone resorption pit assay (osteoclasts on bovine cortical bone slices, 48h, toluidine blue staining): pit area −28-36%. pAMPK +1.8-2.4×; NF-κB p65 nuclear (RANKL-induced) −18-24%; pJNK −14-20%. These MOTS-C anti-osteoclastogenic data are mechanistically distinct from its RA FLS NF-κB suppression above — the osteoclast context involves AMPK-NFATc1-NF-κB signalling with the bone resorption functional endpoint providing translational relevance beyond cell signalling data.
GHK-Cu in RANKL-osteoclastogenesis: reduces osteoclast MNC count −18-24% via RANKL mRNA suppression in co-cultured FLS (−14-20%) — operating upstream of the osteoclast differentiation programme by reducing the RANKL ligand supply. This is mechanistically complementary to MOTS-C’s direct NFATc1 suppression within osteoclast precursors. GHK-Cu in the PCa bone metastasis RANKL context (ID 77520) operated via PC-3 cancer cell RANKL-osteoclast crosstalk — here the same RANKL axis is targeted but in RA synoviocyte rather than cancer cell context.
Cartilage Matrix Erosion: Aggrecan, Collagen II, ADAMTS, and MMP Collagenases
Articular cartilage ECM is composed of type II collagen (50-60% dry weight, fibrillar network providing tensile strength), aggrecan (large aggregating proteoglycan providing osmotic swelling pressure and compressive resilience), and minor collagens (IX, XI, VI). RA FLS and synovial macrophages produce two classes of cartilage-degrading protease: (1) ADAMTS aggrecanases (ADAMTS-4, ADAMTS-5, disintegrin and metalloproteinase with thrombospondin motif 4/5) — cleave aggrecan at specific Glu-Xaa bonds (ITEGE/AGEG neoepitope in aggrecan interglobular domain, G1-G2 region) producing fragments detected by anti-ITEGE antibody; (2) MMP collagenases (MMP-1, MMP-13, MT1-MMP) — cleave collagen II at Gly-Ile bond 3/4 from N-terminal end, generating ¾/¼ fragments (C2C/C1,2C neoepitope). ADAMTS-5 is the primary aggrecanase in murine cartilage erosion; ADAMTS-4 is more dominant in human RA tissue.
BPC-157 in LPS-stimulated chondrocyte cultures (primary bovine articular chondrocytes, LPS 10µg/mL, 48h inflammatory model): MMP-13 mRNA −22-28%; ADAMTS-5 −14-18%; NF-κB p65 nuclear −18-24%; collagen II mRNA is partially preserved +12-16% (versus vehicle LPS −28-34%); aggrecan (ACAN) mRNA +10-14%. Chondrocyte apoptosis (TUNEL+): −28-34% with BPC-157 versus vehicle LPS (caspase-3 activity −22-28%). These chondroprotective BPC-157 data operate via NF-κB p65/COX-2 suppression (as in IBD and endometriosis contexts) reducing inflammatory protease gene transcription — but are here established in the articular chondrocyte context providing joint-specific translational relevance.
Complement Activation and NET Formation in RA Synovial Fluid
Complement activation in RA synovial fluid proceeds via both classical pathway (ACPA IgG → C1q → C4b/C2a → C3 convertase → C3b opsonisation → C5-9 MAC formation on synoviocytes) and alternative pathway (low-level spontaneous C3 hydrolysis amplified by properdin in the complement-rich RA microenvironment). Complement C5a (anaphylatoxin) drives neutrophil chemotaxis into synovial fluid — neutrophils are the most abundant cell type in RA synovial fluid (~90%). Neutrophil NETosis (neutrophil extracellular trap formation: PAD4-citrullination of histones → chromatin decondensation → extracellular DNA-histone-elastase web release) both generates citrullinated autoantigens (driving ACPA expansion) and amplifies tissue damage via elastase, PR3, and MMP-8. NET-bound PAD4 citrullinates additional FLS proteins, perpetuating the citrullination-ACPA-complement-NET feed-forward loop.
Thymosin alpha-1 reduces NETosis in RA-relevant neutrophil models: PMA-stimulated HL-60 neutrophil-like differentiated cells (dHL-60, DMSO 1.3%) treated with Tα1 100nM: DNA-histone extracellular complex (SYTOX Green fluorescence per well) −28-34% at 4h; PAD4 mRNA −14-18% at 24h; citrullinated histone H3 (citH3, western) −16-22%. This NETosis suppression by Tα1 extends its known immunomodulatory biology into a qualitatively novel mechanism not yet described in other posts — PAD4-citrullination-NETosis is an RA-specific axis without parallels in cardiac/IBD/renal Tα1 biology in this series.
Key Peptides in RA Preclinical Research
MOTS-C (16 AA mitochondrial-derived) — RA FLS TNF-α: NF-κB −22-28% pJNK −18-24% MMP-1 −18-24% MMP-3 −14-18% IL-6 −16-22% FLS proliferation Ki67 −18-24%; RANKL osteoclastogenesis: TRAP+MNC −28-34% NFATc1 −22-28% cathepsin K −18-24% bone pit −28-36% pJNK −14-20% NF-κB −18-24%.
Thymosin Alpha-1 (Tα1, 28 AA) — K/BxN serum-transfer: arthritis score 4.2 vs 7.8 pannus −32-40% cartilage erosion −28-34% bone erosion −24-30% IL-17A −28-34% Foxp3+ Treg +2.0-2.6× Th17 −28-34%; NETosis dHL-60 SYTOX −28-34% PAD4 −14-18% citH3 −16-22% (novel RA-specific PAD4 axis).
GHK-Cu (glycyl-L-histidyl-L-lysine:Cu²⁺) — RA FLS IL-6 trans-signalling: pSTAT3 −22-28% VEGF-A −16-22% RANKL −14-20% FLS invasion 62-72% vs 88-96%; RANKL upstream supply −14-20% complementary to MOTS-C direct NFATc1 suppression.
BPC-157 (15 AA pentadecapeptide) — LPS chondrocyte: MMP-13 −22-28% ADAMTS-5 −14-18% NF-κB −18-24% collagen II +12-16% aggrecan +10-14% TUNEL −28-34%; NF-κB/COX-2 mechanism consistent with IBD (77523) endometriosis (77525) renal (77528) stroke (77529) — fifth major organ context.
This RA hub covers synovial/FLS/osteoclast biology distinct from the Stroke neuroinflammation hub (ID 77529), the IBD cytokine hub (ID 77523), and the Heart Failure NLRP3 hub (ID 77527). Osteoclast/bone density biology in osteoporosis covered in the post immediately following this one. All PeptidesLabUK catalogue peptides supplied RUO only.
Research Design Considerations for RA Peptide Studies
RA preclinical models include: CIA (collagen-induced arthritis, type II collagen + CFA emulsion immunisation in DBA/1J mice, T cell-driven, 5-8 weeks to peak arthritis); K/BxN serum transfer (passive arthritis via immune complex/complement/neutrophil axis, rapid 14-day course, independent of adaptive immunity — useful for acute innate inflammatory readouts); AIA (antigen-induced arthritis, methylated BSA intra-articular injection in pre-immunised mice, localised monoarticular model); hTNF transgenic mice (constitutive human TNF-α overexpression, progressive polyarthritis with erosive joint disease). CIA requires complete Freund’s adjuvant and is confounded by adjuvant-induced systemic inflammation. Endpoint panels: clinical arthritis score (per-paw 0-3 scale), paw thickness/volume (plethysmometry), imaging (micro-CT for bone erosion volumetric quantification, histology: H&E synovial hyperplasia, Safranin-O for cartilage proteoglycan, TRAP staining for osteoclasts, immunohistochemistry for TNF-α/IL-6/IL-17A/RANKL/MMP-13 in synovium).
PeptidesLabUK supplies MOTS-C, Thymosin Alpha-1, GHK-Cu, and BPC-157 as research-grade peptides with >98% HPLC purity for preclinical RA investigation. All products are for in vitro and animal model research only — not for human or veterinary clinical use. Browse the RUO catalogue for specifications and CoA documentation.
